CARsgen Therapeutics Holdings Limited (2171)의 가격은 얼마입니까?

CARsgen Therapeutics Holdings Limited (2171)의 가격은 $1.72입니다.

CARsgen Therapeutics Holdings Limited (2171)의 시가 총액은 무엇입니까?

CARsgen Therapeutics Holdings Limited (2171)의 시가 총액은 $981.92M입니다.

CARsgen Therapeutics Holdings Limited (2171) 발행주식수

CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.

연도	발행 주식 수	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

발행 주식 수

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	발행 주식 수	차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	478.91M	-	AU
Moderna, Inc. MRNA.US	396.00M	-	US
Lonza Group AG LONN.SW	-	-	CH

회사

발행 주식 수

차이

국가